Zealand Pharma disappoints with diabetes drug in phase III

Crucial phase III trial with biotech firm Zealand Pharma's drug hope dasiglucagon did not live up to the hopes of the company and its investors.
Photo: Stine Bidstrup/Ritzau Scanpix
Photo: Stine Bidstrup/Ritzau Scanpix

Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading